Welcome to our dedicated page for LeMaitre Vascular news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on LeMaitre Vascular stock.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a leading provider of medical devices and implants for the treatment of peripheral vascular disease, a condition that affects over 200 million people globally. The company develops, manufactures, and markets disposable and implantable vascular devices aimed at addressing the needs of vascular surgeons. LeMaitre Vascular offers a diversified product portfolio that includes angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.
Headquartered in Burlington, Massachusetts, LeMaitre's products are utilized during open vascular surgeries, primarily focusing on several anatomical areas such as the carotid, lower extremities, upper extremities, and aorta. The company's lower extremities product line generates the highest revenue, followed by the carotid product line. In recent financial updates, the company reported significant growth in sales across various product categories including bovine patches, valvulotomes, and carotid shunts.
LeMaitre Vascular continues to demonstrate robust financial health. For Q3 2023, the company reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies. Operating income for Q4 2023 was up 46%, reflecting strong sales growth and improved gross margins. In addition, LeMaitre has a share repurchase program and regularly pays dividends to its shareholders, exemplifying its commitment to shareholder value.
Furthermore, LeMaitre Vascular is focused on expanding its global footprint. Sales in the Americas, EMEA, and APAC regions have shown substantial growth, contributing significantly to the company's revenue. The company also emphasizes compliance with global regulatory requirements, ensuring that its products meet stringent quality standards.
LeMaitre frequently engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. The company remains committed to innovation and development, constantly working on new projects to enhance its product offerings and address emerging market needs.
For more information about LeMaitre Vascular and its latest updates, visit their official website at www.lemaitre.com.
LeMaitre Vascular (LMAT) has secured an exclusive distribution agreement for Aziyo Biologics' cardiovascular patches in the U.S. for three years, with an option to acquire Aziyo's worldwide cardiovascular patch business during the second and third year. The patches, including ProxiCor®, VasCure®, and Tyke®, utilize an extracellular matrix aimed at reducing inflammation and promoting healthy tissue formation. Aziyo reported $6.8 million in sales from these patches in 2022. LeMaitre anticipates a 50% gross margin from patch sales. President David Roberts expressed enthusiasm about enhancing the company's product offerings for vascular and cardiac surgeons. Further financial implications of this agreement will be detailed in LeMaitre’s Q1 2023 earnings call on May 2, 2023.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will announce its Q1 2023 financial results on May 2, 2023, after market closure. A conference call is scheduled for 5:00 PM ET on the same day to discuss the results and outlook for the company. Interested parties can register for the call here. The company provides devices and services for treating peripheral vascular disease, impacting over 200 million people globally, and focuses on the needs of vascular surgeons.
LeMaitre Vascular (Nasdaq: LMAT) announced the acquisition of its Thai distributor, Prompt Serve, for $688,000. In 2022, Prompt Serve sold approximately $1.5 million of LeMaitre products to Thai hospitals. This acquisition will enable LeMaitre to establish a direct sales presence in Thailand, marking its 29th direct-to-hospital country and 8th in the APAC region. Jacob Petersen, VP of Asia-Pacific, noted this move is part of their ongoing expansion, aiming for over 90% of operations to be direct in the APAC market. Further financial guidance regarding the impact on 2023 revenue and earnings will be provided during the Q1 earnings call.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will participate in four investor conferences in March 2023. Key events include the 35th Annual Roth Conference on March 13, featuring President David Roberts in a fireside chat at 12:30 PM PT. On March 15, the Oppenheimer 33rd Annual Healthcare Conference will feature CFO JJ Pellegrino at 8:40 AM ET, followed by Roberts presenting at the Barclays Global Healthcare Conference at 2:35 PM ET. Finally, on March 22, Roberts will present at the KeyBanc Life Sciences & MedTech Investor Forum at 3:00 PM ET. LeMaitre provides innovative devices for peripheral vascular disease, serving a global market of over 200 million patients.
LeMaitre (Nasdaq:LMAT) reported Q4 2022 results showing a 4% increase in sales to $41.0 million, with organic sales growth of 8%. Operating income fell 16% to $7.0 million, while net income declined 9% to $5.6 million, resulting in earnings per share of $0.25. The gross margin decreased to 63.6% due to a strong dollar. The company announced a quarterly dividend of $0.14/share (+12%) and provided optimistic guidance for Q1 2023, expecting sales of $42.6 million to $45.0 million (+11%). Full-year sales guidance is projected at $174.3 million to $178.3 million (+9%). A stock repurchase program of $25 million was also authorized.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) will announce its fourth quarter 2022 financial results on February 23, 2023, after market close. Following the release, a conference call is scheduled for 5:00 PM ET to discuss the results, business highlights, and outlook for the company. LeMaitre specializes in devices, implants, and services for treating peripheral vascular diseases affecting over 200 million globally. The company's portfolio addresses the needs of vascular surgeons, with a focus on disposable and implantable vascular devices.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two significant investor conferences. David Roberts, President, will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 3:10 PM ET in New York City. Additionally, he will present at the Sidoti Small-Cap Virtual Conference on December 8, 2022, at 1:15 PM ET. LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million individuals globally.
FAQ
What is the current stock price of LeMaitre Vascular (LMAT)?
What is the market cap of LeMaitre Vascular (LMAT)?
What products does LeMaitre Vascular offer?
Where is LeMaitre Vascular headquartered?
In which medical areas are LeMaitre's products primarily used?
What was the company's financial performance in Q3 2023?
How does LeMaitre Vascular engage with its investors?
What regions contribute significantly to LeMaitre's revenue?
Does LeMaitre Vascular pay dividends to its shareholders?
What recent financial achievements has LeMaitre Vascular reported?
How does LeMaitre ensure the quality of its products?
Where can I find more information about LeMaitre Vascular?
